

# Amy Jo Chien

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8607147/publications.pdf>

Version: 2024-02-01

22  
papers

1,815  
citations

586496

16  
h-index

759306

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

2869  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Emerging immunotherapeutic strategies for the treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 243-255.   | 1.1  | 4         |
| 2  | Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorshipâ€“Associated Distress: Survey Study. <i>JMIR Cancer</i> , 2022, 8, e31756.   | 0.9  | 0         |
| 3  | Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. <i>Current Breast Cancer Reports</i> , 2021, 13, 164-170.  | 0.5  | 1         |
| 4  | Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1092-1092.  | 0.8  | 3         |
| 5  | Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAMoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 2455-2463. | 1.2  | 8         |
| 6  | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.  | 3.4  | 42        |
| 7  | The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. <i>Npj Breast Cancer</i> , 2021, 7, 156.   | 2.3  | 8         |
| 8  | Fertility preservation before breast cancer treatment appears unlikely to affect diseaseâ€“free survival at a median followâ€“up of 43Âmonths after fertilityâ€“preservation consultation. <i>Cancer</i> , 2020, 126, 487-495.  | 2.0  | 43        |
| 9  | Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. <i>Npj Breast Cancer</i> , 2020, 6, 48.  | 2.3  | 21        |
| 10 | Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.   | 3.4  | 119       |
| 11 | Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. <i>Cancers</i> , 2020, 12, 1511.  | 1.7  | 9         |
| 12 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.             | 0.8  | 69        |
| 13 | A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. <i>Npj Breast Cancer</i> , 2019, 5, 17.  | 2.3  | 19        |
| 14 | Fertility preservation with ovarian stimulation and time to treatment in women with stage IIâ€“III breast cancer receiving neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 151-159.   | 1.1  | 47        |
| 15 | Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. <i>Human Reproduction</i> , 2017, 32, 2123-2129.  | 0.4  | 59        |
| 16 | Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.  | 13.9 | 467       |
| 17 | Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.  | 13.9 | 301       |
| 18 | A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 521-530.  | 1.1  | 27        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 173-181.                            | 1.1 | 17        |
| 20 | Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 524-524. | 0.8 | 27        |
| 21 | Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. <i>Cancer</i> , 2012, 118, 1710-1717.                                       | 2.0 | 430       |
| 22 | Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. <i>Seminars in Oncology</i> , 2008, 35, S1-S14.  | 0.8 | 75        |